Announcements Trials
Browse Landscape

Phase

Phase 2 13Phase 3 5Phase 1 2Phase NA 1Phase 1/2 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 15CNS 12Sarcoma 8Other hematologic neoplasm 7Dermatologic 3Plasma cell 2Other solid neoplasm 2Gastrointestinal 2Breast 1

Conditions

Multiple Myeloma 2Neoplasms, Plasma Cell 1Leukemia, Plasma Cell 1Leukemia 1

Interventions

Dexamethasone 139Lenalidomide 75Cyclophosphamide 73Bortezomib 73Calcium Dobesilate 57fludarabine 49pomalidomide 43daratumumab 39fludarabine phosphate 34carfilzomib 33Melphalan 29dexamethasone acetate 24dexamethasone 21-phosphate 24auricularum 22Filgrastim 18Whole-Body Irradiation 15Biopsy 14ixazomib 13isatuximab 13Magnetic Resonance Spectroscopy 13Granulocyte Colony-Stimulating Factor 13Vorinostat 12Tacrolimus 12Specimen Handling 12Sirolimus 12Peripheral Blood Stem Cell Transplantation 12venetoclax 11belantamab mafodotin 11Rituximab 11Panobinostat 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Carmustine × Plasma cell × Clear all
NCT02504359 2020-11-23

Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma

OHSU Knight Cancer Institute

Phase 1 Completed
11 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma, Neoplasms, Plasma Cell

NCT00477035 2017-01-11

Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies

Stanford University

Phase 1 Completed
22 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡